Feedback

The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation

Affiliation
Department of Pathology ,Daegu Catholic University School of Medicine ,Daegu ,South Korea
Sung, Woo Jung;
Affiliation
Department of Physiology ,Daegu Catholic University School of Medicine ,Daegu ,South Korea
Kim, Dohyang;
Affiliation
Department of Physiology ,Daegu Catholic University School of Medicine ,Daegu ,South Korea
Zhu, Anlin;
Affiliation
College of Pharmacy ,Chonnam National University ,Gwangju ,South Korea
Cho, Namki;
Affiliation
Biometrology Group ,Korea Research Institute of Standards and Science ,Daejeon ,South Korea
Yoo, Hee Min;
Affiliation
Department of Biochemistry ,Chungnam National University ,Daejeon ,South Korea
Noh, Ji Heon;
Affiliation
Department of Biological Sciences ,Chungnam National University ,Daejeon ,South Korea
Kim, Kyoung Mi;
Affiliation
Department of Physiology ,Daegu Catholic University School of Medicine ,Daegu ,South Korea
Lee, Hyun-Su;
Affiliation
Department of Physiology ,Daegu Catholic University School of Medicine ,Daegu ,South Korea
Hong, Jaewoo

EGFR-mediated tumors have been targeted to overcome several different malignant cancers. EGFR overexpression and mutations are directly related to the malignancy, which makes the therapy more complicated. One reason for the malignancy is the induction of AP1 followed by inflammation via IL-6 secretion. Current therapeutic strategies to overcome EGFR-mediated tumors are tyrosine kinase inhibitors (TKIs), anti-EGFR monoclonal antibodies, and the combination of these two agents with classic chemotherapy or immune checkpoint inhibitors (ICIs). Although the strategies are straightforward and have shown promising efficacy in several studies, there are still hurdles to overcoming the adverse effects and limited efficacy. This study reviews the current therapeutic strategies to target EGFR family members, how they work, and their effects and limitations. We also suggest developing novel strategies to target EGFR-mediated tumors in a novel approach. A lysosome is the main custodial staff to discard unwanted amounts of EGFR and other receptor tyrosine kinase molecules. Targeting this organelle may be a new approach to overcoming EGFR-mediated cancers.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Sung, Kim, Zhu, Cho, Yoo, Noh, Kim, Lee and Hong.

Use and reproduction: